We came across a bullish thesis on Novo Nordisk A/S on The Analyst’s Journal’s Substack by A_Capital. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S’s share was trading at $56.72 as of October 15th. NVO’s trailing and forward P/E were 14.98 and 14.08, respectively according to Yahoo Finance.
Novo Nordisk A/S represents a compelling long-term growth opportunity, underpinned by its dominant positions in diabetes and obesity care. The Danish...
